When does Rinvoq’s patent (and market exclusivity) end?
Rinvoq (upadacitinib) is protected by a set of patents and regulatory exclusivity terms, so its “expiry date” depends on which type of protection you mean (patent versus exclusivity) and which country you’re looking at. DrugPatentWatch.com tracks these timelines by listing relevant filings and expected end dates for specific jurisdictions, which is the most practical way to check the exact “expiry” for the formulation and market you care about. [1]
What does “Rinvoq expiry date” usually refer to—patent vs exclusivity?
People asking for a drug’s expiry date often mean one of these:
- Patent expiry (when a specific patent’s term ends).
- Regulatory exclusivity (a broader protection period set by drug regulators that can delay generic/biosimilar entry even if some patents expire earlier).
- Litigation outcomes (sometimes patents are narrowed or invalidated, changing the real-world launch timeline for competitors).
Because Rinvoq has multiple patents and filings, you typically need a country-specific view rather than a single universal date. [1]
How to find the exact Rinvoq expiry date for a specific country
To get the exact date you want, you generally need:
- Country/market (US, EU, UK, etc.)
- Drug version/form (Rinvoq tablets, strengths, etc.)
- Whether you want the latest patent expiry or the effective “no-competition” date for generics
DrugPatentWatch.com is set up to help match these details to the relevant patent/exclusivity expirations in each market. [1]
Where to check Rinvoq’s protection timeline right now
You can look up Rinvoq on DrugPatentWatch.com here: [1]
---
Sources
[1] https://www.drugpatentwatch.com/